Akebia director files initial insider report

Akebia Therapeutics, Inc. has filed an initial insider report identifying Philip J. Vickers as a reporting person in his role as a director.

Rhea-AI Filing Summary

Akebia Therapeutics, Inc. has filed an initial insider report identifying Philip J. Vickers as a reporting person in his role as a director. The filing data show no reported transactions, no derivative positions, and no holding entries associated with him in this Form 3.

Key Figures

Reported buy transactions: 0 transactions Reported sell transactions: 0 transactions Holding entries: 0 entries +2 more

5 metrics

Reported buy transactions 0 transactions Form 3 transaction summary for Philip J. Vickers

Reported sell transactions 0 transactions Form 3 transaction summary for Philip J. Vickers

Holding entries 0 entries Form 3 transaction summary holdingEntries field

Derivative transactions 0 transactions Form 3 derivativeTransactionCount field

Net buy/sell shares 0 shares Form 3 netBuySellShares field

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Akebia Therapeutics' Form 3 for Philip J. Vickers show?

The Form 3 data identify Philip J. Vickers as a director and reporting person at Akebia Therapeutics, Inc. It shows no reported transactions, derivative positions, or holding entries associated with him in this filing.

Are any share transactions reported for Philip J. Vickers in Akebia (AKBA)'s Form 3?

No share transactions are reported. The transaction summary in the data shows zero buy, sell, acquire, dispose, or other transactions, and net buy-sell shares of zero for Philip J. Vickers in this Form 3.

Does the Akebia (AKBA) Form 3 show any derivative securities for Philip J. Vickers?

No derivative securities are shown. The derivative summary is empty, and the transaction summary indicates zero derivative transactions and zero exercise shares for Philip J. Vickers in this initial insider report.

Is Philip J. Vickers a ten percent owner of Akebia Therapeutics, Inc.?

According to the Form 3 data, Philip J. Vickers is not listed as a ten percent owner. He is identified as a director, with the ten percent owner indicator set to zero in the reporting person details.

Does Akebia (AKBA)'s Form 3 show any existing holdings for Philip J. Vickers?

The provided data indicate no existing holdings. The transaction summary lists zero holding entries, and there are no positions shown in the derivative summary for Philip J. Vickers in this initial filing snapshot.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/03/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Vickers Philip J.

(Last) (First) (Middle)

C/O AKEBIA THERAPEUTICS, INC

245 FIRST STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/01/2026

3. Issuer Name and Ticker or Trading Symbol
Akebia Therapeutics, Inc. [ AKBA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

No securities are beneficially owned.

	/s/ Carolyn M. Rucci, attorney-in-fact for Philip J. Vickers	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)